Please use this identifier to cite or link to this item:
Authors: Farabi, Banu
Seminario-Vidal, Lucia
Jamgochian, Marielle
Akay, Bengu Nisa
Atak, Mehmet Fatih
Rao, Babar K.
Karagaiah, Priyanka
Grabbe, Stephan
Goldust, Mohamad
Title: Updated review on prognostic factors in mycosis fungoides and new skin lymphoma trials
Online publication date: 6-Sep-2022
Year of first publication: 2022
Language: english
Abstract: Background Ten-year survival rates in mycosis fungoides (MF) broadly varies, however, there is no standardized prognostic index available. This is presumably due to low prevalence, heterogeneity, and diagnostic challenges in MF. Recent studies have focused on identifying objective prognostic indices by using different parameters for survival determinants. The Cutaneous Lymphoma International Prognostic Index (CLIPI) and the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) represent prototypical studies that identify prognostic factors, seeking to improve management and outcomes in early-stage MF. Detecting these factors and stratifying MF patients according to their disease progression risk may help to manage these patients more efficiently. Aims Review the current literature to determine the risk factors determining prognosis in MF. Methodology A Comprehensive literature search was performed using electronic online databases "PubMed" and "Google Scholar" using key words ‘prognostic factor’, ‘prognostic indicator’, ‘mycosis fungoides’, ‘Sezary syndrome’, ‘Skin Lymphoma’, ‘Cutaneous Lymphoma’. Articles published in English language were considered for the review. Results The strongest prognostic factor in MF patients is the stage of the disease. T stage and the presence of extracutaneous disease are the most important factors for survival. Other factors that are associated with worse prognosis are male gender, age >60, presence of plaques, folliculotropism, eosinophilia and lymph node stage above N1/Nx. Elevated LDH was associated with later tumor stages and large cell phenotype at diagnosis had a better prognosis. KIR3DL2 was associated with malignant transformation. Conclusion The PROCLIPI study has assessed risk factors collected in MF patients from different countries and across different ethnicities following a rigorous clinicopathologic process. The findings presented here illustrated that disease prognosis in early stages depends on many contributing factors. Detection and stratification of such factors may allow a personalized approach to management of these patients.
DDC: 610 Medizin
610 Medical sciences
Institution: Johannes Gutenberg-Universität Mainz
Department: FB 04 Medizin
Place: Mainz
Version: Published version
Publication type: Zeitschriftenaufsatz
Document type specification: Review
License: CC BY-NC
Information on rights of use:
Journal: Journal of cosmetic dermatology
Pages or article number: 2742
Publisher: Wiley-Blackwell
Publisher place: Oxford
Issue date: 2022
ISSN: 1473-2165
Publisher DOI: 10.1111/jocd.14528
Appears in collections:JGU-Publikationen

Files in This Item:
  File Description SizeFormat
updated_review_on_prognostic_-20220906114605488.pdf266.38 kBAdobe PDFView/Open